Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397727 | 0.87 | CD38 (0.43) | METAP2PARP1ALDH1A1MAPTKDM4E | |
| SCHEMBL39964 | 0.84 | KDM4E (0.52) | METAP2PARP1ALDH1A1MAPTKDM4E | |
| SCHEMBL11089840 | 0.83 | PRNP (0.47) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL4562961 | 0.82 | PARP1 (0.50) | METAP2PARP1ALDH1A1MAPTKDM4E | |
| SCHEMBL29621571 | 0.81 | TSHR (0.52) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL211283 | 0.81 | TSHR (0.52) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL6469935 | 0.81 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL3117625 | 0.81 | ERN1 (0.47) | PARP1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL4443208 | 0.81 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL3710686 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650993-B | PD-1/PD-L1 inhibitor and preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115232125-B | Polysubstituted benzene immunomodulatory compounds, composition and application thereof | 杭州和正医药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115232125-A | Multi-substituted benzene immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2021047556-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 上海长森药业有限公司 | 2021-03-18 | — | — | WO | disclosed |
| CN-107635970-B | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2020247789-A1 | PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007076247-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076247-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | METAP2 2120/4885PARP1 1483/4885ALDH1A1 4319/4885 |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | METAP2 2120/4885PARP1 1483/4885ALDH1A1 4319/4885 |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | METAP2 549/4885PARP1 1634/4885ALDH1A1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.